healthcare sector in india monthly update december 2012

7/29/2019 Healthcare Sector in India Monthly Update December 2012

http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-december-2012 1/12

Healthcare Sector in India

Monthly Update

December 2012



Healthcare Sector – Monthly Update

Top Story

CSTM to initiate stem cell course

The Calcutta School of Tropical Medicine (CSTM) has decided to initiate a fellowship coursein stem cell biology that happens to be the 1st ever in India. The post‐graduate programme —

Regeneration Medicine and Translational Science has already received consent from the

West Bengal State Health Department. The course will be offered to students who have

completed their MBBS degree course for which 20 such students have already been

shortlisted for 2013 1st batch.

The course that CSTM will commence shortly is available currently only in reputed

universities such as Translational Centre for Regenerative Medicine in Germany and

University of Liverpool and Stanford University. The course is aimed at teaching how dead

tissues of brain, kidney could be used in various purposes for clinical research. The

programme will help push forth Indis’s position in stem cell therapy a step ahead.

News Update

General

Venus to conduct final stage clinical trial of NCE VRP1620

Venus Remedies Ltd. has acquired the approval to conduct phase III clinical trial of cancer

detecting New Chemical Entity (NCE) from the Drugs Controller General of India (DCGI). The

phase III clinical trial for the early cancer detection molecule VRP1620 will involve aninvestment of approximately INR 55 mn.

Venus is in plans to launch the NCE by the end of calendar year 2013 in domestic and

international market. Presently, across the globe there is no technology for early detection of

small‐sized solid tumours. With expected launch of the product that the company claims to

keep at an affordable price there will be a major breakthrough in oncology therapeutic

branch.

UK government keen on upgrading Indian primary healthcare

The UK government is in plans of partnering with India’s primary healthcare segment. It is

working towards partnerships with such primary healthcare segments with the intention of uplifting their treatment standards. UK government has already initiated a pilot project in

partnership with Kerala government for upgrading 3 government‐run primary healthcare

centres of the Thiruvananthapuram district.

The partnerships can take place through public private partnerships (PPPs) and also at the

private level where business houses and corporate entities can venture into collaborations

with UK hospitals and General Practitioner (GP) networks.




Glenmark ties up with Forest Laboratories

Glenmark Pharmaceuticals SA (GPSA) has signed a pact with US based Forest Laboratories

Inc. for drug molecules development for treatment of chronic inflammation. Glenmark has

already identified clinical candidates and is conducting pre‐clinical studies and otherdevelopment activities required to support initiation of first‐in‐human dosing.

As per the agreement, Glenmark will receive INR 500 mn in part payment from Forest

Laboratories for development of mPGES‐1 inhibitors that will treat chronic inflammation

including pain. A part of the payment will be made upfront while the remaining will be made

to support the next phase of work.

Aurobindo Pharma to launch Ondansetron injections

Hyderabad based Aurobindo Pharma Ltd. has received has obtained final approval from US

Food & Drug Administration (USFDA) for manufacture and marketing of Ondansetron

injections. The injection is for the prevention of nausea and vomiting associated with initialand repeat courses of emetogenic cancer chemotherapy or postoperative nausea and/or

vomiting.

The Ondansetron injection will be available in USP 2rng/mL packaged in 40mg/20mL

multiple‐dose vials and USP 2mg/mL packaged in 4mg/2mL single‐dose vials. The product is

already ready for launch in US market.

News Update

Regulatory

Formal decision on drug pricing released

The Indian government has made its final decision of enforcing the new policy that will bring

more generic medicines under price control. The policy will extend price restrictions to 348

"essential" drugs inclusive of cancer and HIV unlike the previous policy that covered barely

74 drug compounds and their combinations. The policy will put a ceiling on the maximum

price of a drug on the basis of average price of all medicines in that category which have a

market share of at least 1%.

India’s cabinet has already approved the policy in late Nov 2012 and will be put to operationsoon. The policy will also embrace imported drugs that are on the "essential" medicines list

and this will ensure not only domestically manufactured but also imported drugs to be

accessible for common man.




Elder inks deal with Holding PharmaEco

Elder Pharmaceuticals Ltd. has entered into an agreement with Russia based Holding

PharmaEco for bilateral co‐operation in healthcare sector. The agreement is part of the 13 th

Annual Indo‐Russian bilateral summit.

India has already earned a good reputation of being a reliable supplier of quality drugs to

Russia. With Russian Government’s Pharma 2020 Programme, Indian pharma companies are

increasingly showing interest in collaborating with Russian partners. The respective

governments of the 2 countries are jointly working towards liberalizing registration

procedure of new drugs to boost bilateral pharma trading activities.

News Update

Expansion Plans

Eli Lily and Strides partner to market oncology drugs

USA based Eli Lilly and Co. and Bangalore based Strides Arcolab has entered into a joint

venture for increasing marketing of oncology products in emerging markets. According to

the agreement Eli Lilly will in‐license a portfolio of branded generic injectible and oral cancer

medicines manufactured by Agila Specialties, the specialties division of Strides Arcolab Ltd.

The deal which had been signed on 5th Dec, 2012 will come into effect from second half of

2013. The deal will sufficiently aid both the companies to capture a greater share of the

market due to their predefined responsibilities.

Defiance Technologies penetrates healthcare sector

Chennai based Defiance Technologies Ltd., the Hinduja Group Company, is venturing into

medical equipment manufacturing – the latest addition to its business of engineering and IT

services for automobile and defence sectors. The company has entered into partnership with

a US‐based R&D company that will aid the firm in re‐designing equipments specifically suited

for the price‐sensitive Indian market.

To understand the Indian medical equipment market that believes in refurbishing

equipments, Defiance has also tied up with two hospitals in Chennai and Bangalore. It also

has plans of entering into such a partnership with its group hospital Hinduja Hospital.Defiance’s business plan is expected to re‐model the Indian healthcare sector that is filled

with low standard refurbished equipments often hampering quality of diagnosis and

treatment for common man.

Claris enters JV with Japanese drug maker Otsuka Pharma & Mitsui

Ahmedabad based Claris Lifesciences Ltd. has entered into a joint venture (JV) with Japan

based pharmaceutical company Otsuka Pharmaceutical and Mitsui & Co Ltd. that has been




named Claris‐Otsuka. The agreement is worth INR 13.13 bn for which Claris will receive INR

10.50 bn over multiple agreements. Shareholding pattern will see Claris owning 20%, Otsuka

Pharma 60% and Mitsui 20%.

As according to the deal, Claris will be responsible for transfer of Common Solutions, Anti‐

Infectives, Plasma Volume Expanders and Parenteral Nutrition therapies business for India

and other emerging markets to Claris‐Otsuka. Claris will also be transferring 2 out of its 5

plants to Claris‐Otsuka. The partnership is a valuable one for Claris as it involves infusions

business expert Otsuka and global trading and financial expertise Mitsui.

Industry Expert Speak

UK government

keen

on

upgrading

Indian

primary

healthcare

– Mike

Nithavrianakis,

British deputy high commissioner in Chennai and ex -officio president of Indo-British

health initiative (IBHI)

“The collaboration can happen in different levels. The state governments can partner with

British entities to upgrade the existing primary health centers (PHCs). Further, there could

be public‐private‐partnerships in primary health care. In the private sector, family‐run

businesses or corporate entities that are keen to enter healthcare can also consider joint

venture partnerships with UK hospitals and GP networks”

Eli Lily and Strides partner to market oncology drugs - Jacques Tapiero, Eli Lilly Senior

Vice President

and

President

of

Eli

Lilly

emerging

markets

division

“The demand for high‐quality cancer medicines is unmet in many markets around the world.

This agreement will help Eli Lilly expand its portfolio and deliver high‐quality cancer

medicines to patients across emerging markets.”

Formal decision on drug pricing released - Manoj Garg, Pharmaceuticals Analyst at

Mumbai -based brokerage Edelweiss Securities Ltd.

"On a broad level, local drug makers will have to cut prices by 20%‐25% across portfolios,

while multinational drug companies will have to reduce rates by between 30% and 50%,"

Glenmark ties up with Forest Laboratories – Glenn Saldanha, Glenmark

Pharmaceuticals Chairman and Managing Director

"This collaboration reinforces our strategy of partnering to achieve our goal of launching

innovative technologies around the world.”




Transaction Detail (Oct – Dec 2012)

Date Buyer Target Deal Size

(INR mn)

% stake Deal Status Type

of

Transaction

17th Dec2012

Bupa AustraliaHealth Pty Ltd.

DentalCorporation

Holdings Ltd

11276 64% Planned M&A

17th Dec2012

CaracoPharmaceutical

URL PharmaN.A. N.A. Planned M&A

15th Dec2012

ErbaDiagnostics

US arm of Transasia

Bio‐MedicalsLtd.

Drew ScientificInc and JAS

Diagnostics Inc,from

Escalon MedicalCorp

N.A. N.A. Completed M&A

11th Dec2012

SutherlandGlobal Services

Apollo Health

Street (AHS)

10000 100% Planned M&A

4th Dec2012

DecisionResources

Group (DRG)Subsidiary of

PiramalEnterprises

AbacusInternational


4th Dec

2012

Matrix Partners

India

Enhance

Aesthetic andCosmetic Studio

Pvt. Ltd.


26th Nov

2012

TrivitronHealthcare Pvt.

Ltd.

Ani Labsystems

Ltd.1221.12 N.A. Completed M&A

22nd Nov

2012IncuCapital

Navigene Genetic

Science Pvt. Ltd.N.A. N.A. Completed Private Equity




21st Nov2012

Cipla Ltd.Cipla Medpro

South Africa Ltd.12101.2 51% Completed M&A

8th Nov2012

Sun PharmaIndustries Ltd.

DUSA

Pharmaceuticals,Inc.

12.65 N.A. Planned M&A

31st Oct 2012

GE EquityInternational

Mauritius

SyngeneInternational

(Biocon Ltd.subsidiary)

1250 7.69 Completed Private Equity

25th Oct

2012

Fidelity India

Capital

Trivitron

Healthcare

4000 35‐40 Planned Private Equity

22nd Oct 2012

Dr. Reddy'sLaboratories

OctoPlus N.V. 1930 100 Planned M&A

17th Oct

2012

Mylan

Laboratories

SMS

Pharmaceuticals’Vishakhapatnam

located

manufacturing

1730 N.A. Completed Acquisition

Annual Financial Results – Revenue (INR mn) – Major Healthcare

Companies Companies FY ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0

Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5

Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7

Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0

Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0




Dr. Reddy’s Laboratories

(DRL)69,441.00 70,277.00 74,693.00 96,737.4

GlaxosmithKlineConsumer Healthcare

Ltd.

19,757.6 23,693.3 27,688.6 28,857.3

Glenmark

Pharmaceuticals Ltd.21,241.20 25,291.30 29,490.70 40,206.4

Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5

Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1

Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0

Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543

Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3

Ranbaxy LaboratoriesLtd.

75,970.40 89,607.70 101,614.1 117,153.2

Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9

Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1

Sun PharmaceuticalsIndustries Ltd.

42,723.00 38,086.30 57,214.30 80,056.6

Torrent PharmaceuticalsLtd.

16,306.60 19,160.40 22,264.80 26,959.2

Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0

Annual Financial Results – Income (INR mn) - Major Healthcare

Companies

Companies FY ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0

Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0


Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4




Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0


(DRL) ‐5,168.00 1,068.00 11,040.00 14,262.1

GlaxoSmithKline Consumer

Healthcare Ltd.2,327.8 2,998.5 3,552.1 3,765.6

Glenmark PharmaceuticalsLtd.

1,916.60 3,244.70 4,532.10 4,603.5

Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6

Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5

Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7


Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0

Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5

Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6


Sun Pharmaceuticals

Industries Ltd.18,177.30 13,510.80 18,160.60 25,872.5

Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4

Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1




Quarterly Financial Results – Revenue (INR mn) – Major Healthcare

Companies Companies

Oct -Dec

2011

Jan-Mar

2012

Apr-Jun

2012

Jul-Sep

2012

Biocon Ltd. 5,171.90 5,892.2 5,770.0 5,924.0

Blue Star Ltd. 5,896.9 N.A. N.A. N.A.


Cipla Ltd. 17,580.00 N.A N.A. N.A.

Dabur India Ltd. 14,526.80 13,858.3 14,620.0 15,226.0


(DRL)27,692.00 26,584.0 25,406.0 28,808.5

GlaxoSmithKline ConsumerHealthcare Ltd.

6,854.0 8,608.7 7,869.6 8,275.4

Glenmark Pharmaceuticals

Ltd.10,310.90 10,751.2 10,404.1 12,551.9

Jubilant life Sciences Ltd. 10,871.70 12,235.9 12,358.9 12,197.3

Lupin Ltd. 17,917.0 20,063.7 22,191.5 22,392.6

Nestle India Ltd. 19,633.2 20,558.7 19,865.8 21,155.9


Piramal Enterprises Ltd. 5,518.30 8,858.0 7,102.9 8,285.8

Ranbaxy Laboratories Ltd. 37,923.1 36,954.0 31,740.6 26,513.9

Siemens India Ltd. 30,458.2 37601.432 33,082.4 32,693.6


Sun PharmaceuticalsIndustries Ltd. 21,451.30 23,299.3 26,581.4 26,572.4

Torrent Pharmaceuticals Ltd. 6,965.9 6,686.8 7,356.0 7,471.7

Wockhardt Ltd. 12,086.70 12,413.90 14,258.2 13,474.4




Companies

Oct -Dec

2011

Jan-Mar

2012

Apr-Jun

2012

Jul-Sep

2012

Biocon Ltd. 848.50 978.0 790.0 896.5

Blue Star Ltd. (327.6) N.A. N.A. N.A.

Cadila Healthcare Ltd. 1,492.10 1,708.8 1,947.9 951.4

Cipla Ltd. 2,699.10 N.A. N.A. N.A.

Dabur India Ltd. 1,728.20 1,705.1 1,494.0 2,023.7


(DRL)5,130.0 3,427.0 3,360.0 4,074.4

GlaxoSmithKline ConsumerHealthcare Ltd.

591.0 1,319.7 1,066.0 1,285.5

Glenmark Pharmaceuticals

Ltd.461.20 1,482.7 782.8 1,567.5

Jubilant life Sciences Ltd. ‐783.90 ‐635.3 50.1 1,520.0

Lupin Ltd. 2,350.60 1,556.4 2,803.9 2,904.6

Nestle India 2,308.30 2,757.3 2,459.7 2,673.1


Piramal Enterprises Ltd. 85.2 ‐386.8 40.8 (920.2)

Ranbaxy Laboratories Ltd. ‐29,827.7 12,467.6 ‐5,857.3 7,541.7

Siemens India Ltd. 1,873.6 3,040.0 (157.8) (557.7)

Strides Arcolab Ltd 684.1 6,420.7 904.8 524.9

Sun Pharmaceuticals

Industries Ltd.6,683.0 8202.1 7,955.5 3,196.4

Torrent Pharmaceuticals Ltd 831.8 ‐16.5 1,018.5 1,072.5

Wockhardt Ltd. 2,128.10 ‐1,916.4 3,779.7 4,535.5

* denotes a change in financial year

Quarterly Financial Results – Income (INR mn) - Major Healthcare

Com anies




Events Calendar

Research on India (ROI) is a leading source for market research on various sectors in India

that offers premium research content from worldwide publishers of market research

reports.

Contact us:

W: https://www.researchonindia.com

T: India (Toll Free): 1800 102 1133; International: +91 (33) 4027 6214/5

E: [email protected]

Connect with

Us

Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.

International Conference on Diabetes and its

Complications

Date: 18th ‐20th Jan 2013

Venue: CHARUSAT Conference Hall, P D PatelInstitute of Applied Sciences Changa, Dist.

Anand, Gujarat Organizer: Charusat Healthcare and Research

Foundation & Charotar University of Science and Technology

Website: www.charusat.ac.in/icdc‐2013/ Contact Person: Dr. Aditi BuchContact No.: +91 9825592847E-mail: [email protected]

Global Healthcare Summit

Date: 1st – 3rd

Jan, 2013 Venue: International Convention Centre, CochinOrganizer: American Association of Physicians of

Indian OriginWebsite: www.aapighsindia.org/ghcs_abt_main.php E- mail: [email protected] and

[email protected]

http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

https://twitter.com/ResearchOnIndia

http://www.facebook.com/researchonindia

healthcare sector in india monthly update december 2012

Documents